| 1 |
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma, David W. Miles, Luca Gianni et al. · New England Journal of Medicine
Open access |
Oct 2012 |
3,859 |
| 2 |
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al. · New England Journal of Medicine
Open access |
16 Nov 2014 |
2,718 |
| 3 |
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2
Barış Türkbey, Andrew B. Rosenkrantz, Masoom A. Haider et al. · European Urology
|
18 Mar 2019 |
2,528 |
| 4 |
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al. · New England Journal of Medicine
Open access |
14 Jun 2012 |
2,179 |
| 5 |
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Rob Glynne‐Jones, Lucjan Stanislaw Wyrwicz, Emmanuel Tiret et al. · Annals of Oncology
Open access |
5 May 2017 |
2,098 |
| 6 |
Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
Anwar R. Padhani, Guoying Liu, Dow‐Mu Koh et al. · Neoplasia
Open access |
Feb 2009 |
2,015 |
| 7 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas David James et al. · New England Journal of Medicine
Open access |
3 Jun 2017 |
1,806 |
| 8 |
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina Venetia Long et al. · The Lancet
|
31 May 2015 |
1,419 |
| 9 |
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert et al. · New England Journal of Medicine
Open access |
4 Jun 2019 |
1,412 |
| 10 |
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher Parker et al. · The Lancet
Open access |
21 Oct 2018 |
1,289 |
| 11 |
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia, Herbert I. Hurwitz, Alan B. Sandler et al. · Cancer Treatment Reviews
Open access |
26 Mar 2020 |
1,180 |
| 12 |
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Adrian Murray Brunt et al. · The Lancet
Open access |
28 Apr 2020 |
1,111 |
| 13 |
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Marie Fallon, Raffaele Giusti, Federica Aielli et al. · Annals of Oncology
Open access |
20 Apr 2018 |
949 |
| 14 |
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
Richard Pötter et al. · Clinical and Translational Radiation Oncology
Open access |
11 Jan 2018 |
946 |
| 15 |
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al. · The Lancet Oncology
222 authors |
12 Mar 2020 |
934 |
| 16 |
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al. · New England Journal of Medicine
Open access |
22 Sep 2021 |
916 |
| 17 |
Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline
Stephen Lutz, Lawrence B Berk, Eric Lin Chang et al. · International Journal of Radiation Oncology*Biology*Physics
|
28 Jan 2011 |
860 |
| 18 |
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert John Motzer et al. · The Lancet Oncology
Open access |
16 Aug 2019 |
797 |
| 19 |
Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study
Marloes van der Leest, Erik Bastiaan Cornel, Bas Israël et al. · European Urology
Open access |
24 Nov 2018 |
787 |
| 20 |
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
David W. Miles et al. · Annals of Oncology
Open access168 authors |
Jul 2021 |
753 |
| 21 |
Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting
Louise Dickinson, Hashim Uddin Ahmed, Clare Allen et al. · European Urology
|
22 Dec 2010 |
736 |
| 22 |
The Lancet Commission on prostate cancer: planning for the surge in cases
Nicholas David James et al. · The Lancet
Open access |
Apr 2024 |
723 |
| 23 |
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Georgina Venetia Long et al. · Annals of Oncology
Open access |
3 May 2017 |
668 |
| 24 |
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
Richard Pötter et al. · The Lancet Oncology
Open access |
29 Mar 2021 |
666 |
| 25 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique C Dieras, David W. Miles, Sunil Verma et al. · The Lancet Oncology
Open access |
16 May 2017 |
666 |
| 26 |
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al. · European Urology
Open access |
24 Jun 2017 |
644 |
| 27 |
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin, Ignace B. Vergote, Elizabeth A. Eisenhauer et al. · International Journal of Gynecological Cancer
Open access |
2011 |
632 |
| 28 |
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
Charlotte Elizabeth Coles et al. · The Lancet
Open access |
2 Aug 2017 |
620 |
| 29 |
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J.S. Rustin, Maria EL van der Burg, Clare L. Griffin et al. · The Lancet
Open access |
Oct 2010 |
602 |
| 30 |
Bone metastases
Robert Edward Coleman, Peter Ian Croucher, Anwar R. Padhani et al. · Nature Reviews Disease Primers
ReviewOpen access |
15 Oct 2020 |
584 |
| 31 |
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
Anne J. Breugom, Marloes Swets, Jean-François Bosset et al. · The Lancet Oncology
Review |
11 Jan 2015 |
582 |
| 32 |
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
David Cunningham, Eliza Anne Hawkes, ANDREW S. JACK et al. · The Lancet
Open access |
22 Apr 2013 |
561 |
| 33 |
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Douglas H. Brand et al. · The Lancet Oncology
Open access |
17 Sep 2019 |
555 |
| 34 |
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver A. Sartor et al. · The Lancet Oncology
|
13 May 2014 |
499 |
| 35 |
General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
Sandra Nolte, Gregor Liegl, Morten Aagaard Petersen et al. · European Journal of Cancer
Open access |
19 Dec 2018 |
479 |
| 36 |
Multidisciplinary team working in cancer: what is the evidence?
Chris Taylor, Alice Munro, Rob Glynne‐Jones et al. · BMJ
Open access |
23 Mar 2010 |
479 |
| 37 |
Copy number signatures and mutational processes in ovarian carcinoma
Geoff Macintyre et al. · Nature Genetics
Open access |
9 Aug 2018 |
466 |
| 38 |
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
Karla A. Lee et al. · Nature Medicine
Open access |
28 Feb 2022 |
465 |
| 39 |
Metastatic disease from uveal melanoma: treatment options and future prospects
Richard D. Carvajal, Gary K. Schwartz, Tongalp H. Tezel et al. · British Journal of Ophthalmology
Open access |
29 Aug 2016 |
455 |
| 40 |
Development of a European Organization for Research and Treatment of Cancer (Eortc) Questionnaire Module to be Used in Quality of Life Assessments in Head and Neck Cancer Patients
Kristin Bjordal, Marianne Ahlner‐Elmqvist, Eva Tollesson et al. · Acta Oncologica
Open access |
1994 |
454 |
| 41 |
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
16 Feb 2023 |
447 |
| 42 |
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
John M. A. Northover, Rob Glynne‐Jones, David Sebag‐Montefiore et al. · British Journal of Cancer
Open access |
Mar 2010 |
434 |
| 43 |
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Christopher Parker et al. · The Lancet
Open access |
28 Sep 2020 |
420 |
| 44 |
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin, Oliver A. Sartor, Joe M. O’Sullivan et al. · The Lancet Oncology
|
17 Oct 2014 |
409 |
| 45 |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
Ian E. Krop, Nancy U. Lin, Kimberly Blackwell et al. · Annals of Oncology
Open access |
30 Oct 2014 |
404 |
| 46 |
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Silke Gillessen et al. · European Urology
Open access |
27 Jan 2020 |
400 |
| 47 |
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlési, Johan Vansteenkiste, David Robert Spigel et al. · The Lancet Oncology
|
24 Sep 2018 |
400 |
| 48 |
Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice
Andrew B. Rosenkrantz, Anwar R. Padhani, Thomas L. Chenevert et al. · Journal of Magnetic Resonance Imaging
Open access |
26 Jun 2015 |
393 |
| 49 |
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
Lisa Lowry, Paul Smith, Wendi Qian et al. · Radiotherapy and Oncology
|
20 Jun 2011 |
389 |
| 50 |
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research
Johannes Maria Giesinger, Fanny L. C. Loth, Neil K. Aaronson et al. · Journal of Clinical Epidemiology
Open access |
19 Oct 2019 |
382 |